| Total number of included studies | Hong [29] | Kaneda [33] | Kernan (IRIS) [2] | Lee [30] | Nishio [34] | Nissen (PERISCOPE) [9] | Suryadevara [31] | Takagi (POPPS) [32] | Tanaka (J-SPIRIT) [8] | |
---|---|---|---|---|---|---|---|---|---|---|---|
Population | |||||||||||
 Type 2 diabetes + CVD | 7 | X |  |  | X | X | X | X | X |  | X |
 Type 2 diabetes + no diabetes + CVD | 1 |  | X |  |  |  |  |  |  |  |  |
 Abnormal glucose metabolism without diabetes + CVD | 2 |  |  | X |  |  |  |  |  | X |  |
 Patients undergoing PCI | 5 | X | X |  | X | X |  |  | X |  |  |
Type of pioglitazone treatment | |||||||||||
 Pioglitazone 15 mg/d | 2 | X |  |  | X |  |  |  |  |  |  |
 Pioglitazone 30 mg/d | 3 |  |  |  |  | X |  | X | X |  |  |
 Pioglitazone 45 mg/d | 1 |  |  | X |  |  |  |  |  |  |  |
 Pioglitazone 15–30 mg/d | 2 |  | X |  |  |  |  |  |  | X |  |
 Pioglitazone 15–45 mg/d | 2 |  |  |  |  |  | X |  |  |  | X |
Treatment in control group | |||||||||||
 None | 4 |  | X |  |  | X |  |  | X | X |  |
 Placebo | 5 | X |  | X | X |  |  | X |  |  | X |
 Glimepiride | 1 |  |  |  |  |  | X |  |  |  |  |
Extracted outcome of interest | |||||||||||
 Major adverse c cardiac/Cardiovascular disease | 8 | X | X | X | X | X | X |  | X |  | X |
 Myocardial infarction | 8 | X | X | X | X | X | X |  | X |  | X |
 Stroke | 4 |  |  | X |  |  | X |  |  | X | X |
 All-cause mortality | 8 |  | X | X | X |  | X | X | X | X | X |
 Heart failure | 6 | X | X | X |  |  | X |  | X | X | X |